

LISTADO DE ARTÍCULOS PUBLICADOS EN 2021

Estudios de promotor GEICAM

ESTUDIO	REVISTA	FACTOR DE IMPACTO	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2013-02 (PEARL)	EJC	9,162	Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer in the PEARL study	Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Muñoz M, Bermejo B, Margeli M, Antón A, Casas M, Csösz T, Murillo L, Morales S, Calvo L, Lang I, Alba E, de la Haba-Rodríguez J, Ramos M, Álvarez López I. M, Gal-Yam E, Garcia-Palomo A, Alvarez E, González-Santiago S, Rodríguez C.A, Servitja S, Corsaro M, Rodríguez G, Zielinski C, Martín M	Eur J Cancer. 2021 Oct;156:70-82. doi: 10.1016/j.ejca.2021.07.004. Epub 2021 Aug 20.
GEICAM/2014-12 (FLIPPER)	EJC	9,162	Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014-12 (FLIPPER)	Albanell J, Martínez M.T, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martínez-Jañez N, Moreno F, Fernández I, Alarcón J, Virizuela J.A, de la Haba-Rodríguez J, Sánchez-Rovira P, González-Cortijo L, Margelí M, Sánchez-Muñoz A, Antón A, Casas M, Bezares S, Rojo F	Eur J Cancer. 2021 Dec 10;161:26-37. doi: 10.1016/j.ejca.2021.11.010. Online ahead of print.
EpiGEICAM-01: Alcohol	Br. J Cancer	7,640	Trajectories of alcohol consumption during life and the risk of developing breast cancer	Donat C, Guerrero-Zotano A, Casas A.M, Baena-Cañada J.M, Lope V, Antolín S, García-Sáenz J.A, Bermejo B, Muñoz M, Ramos M, de Juan A, Jara C, Sánchez-Rovira P, Antón A, Brunet J, Gavilá Gregori J, Salvador Bofill J, Arriola Arellano E, Bezares S, Fernández de Larrea-Baz N, Pérez-Gómez B, Martín M, Pollán M	Br J Cancer. 2021 Oct;125(8):1168-1176. doi: 10.1038/s41416-021-01492-w. Epub 2021 Sep 6.

ESTUDIO	REVISTA	FACTOR DE IMPACTO	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2015-04 (PANGEA-Breast)	Cancers (special issue)	6.1	Pembrolizumab plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study	de la Cruz-Merino L, Gion M, Cruz J, Quiroga V, Andrés R, Moreno F, Alonso-Romero J.L, Ramos M, Holgado E, Cortés J, López-Miranda E, Henao F, Palazón-Carrión N, Rodríguez L.M, Ceballos I, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F	Cancers (Basel). 2021 Oct 29;13(21):5432. doi: 10.3390/cancers13215432. PMID: 34771596; PMCID: PMC8582406.

Colaboraciones con otros promotores, con autoría GEICAM

ESTUDIO	REVISTA	FACTOR DE IMPACTO	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA COMPLETA
GEICAM/2011-03 (RXPONDER) - GEICAM/2012-01	NEJM	91,25	21-Gene Assay to Inform Chemotherapy	Kalinsky K, Barlow W.E, Gralow J.R, Meric-Bernstam F, Albain K.S, Hayes D.F, Lin N.U, Perez E.A, Goldstein L.J, Chia S.K.L, Dhesy-Thind S, Rastogi P, Alba E, Delalogue S, Martin M, Kelly C.M, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas C.H, Brain E.G.C, Lee E. S, Pierga J.Y, Bermejo B, Ramos-Vazquez M, Jung K.H, Ferrero J.M, Schott A.F, Shak S, Sharma P, Lew D.L, Miao J, Tripathy D, Puztai L, and Hortobagyi G.N	N Engl J Med 2021; 385:2336-2347 doi: 10.1056/NEJMoa2108873
GEICAM/2014-07 PALLAS	Lancet Oncology	41,32	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study	Mayer E.L, Dueck A.D, Martin M, Rubovszky G, Burstein H.J, Bellet-Ezquerria M, et al.	Lancet Oncol . 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2.
GEICAM/2014-11 (AURORA)	Cancer Discovery	39,40	Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative	Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdottir A, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Lasa Montoya M, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ.	Cancer Discov. 2021 Nov;11(11):2796-2811. doi: 10.1158/2159-8290.CD-20-1647. Epub 2021 Jun 28.

ESTUDIO	REVISTA	FACTOR DE IMPACTO	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2013-03 (PENELOPEB)	JOURNAL OF CLINICAL ONCOLOGY	28,25	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial	Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim S, Bear H, McCarthy N, Olivé M.M, Gelmon K, García-Sáenz J.A, Kelly C.M, Reimer T, Toi M, Rugo H.S, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Freañ M.J, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G	J Clin Oncol. 2021 May 10;39(14):1518-1530. doi: 10.1200/JCO.20.03639. Epub 2021 Apr 1.
GEICAM/2014-07 PALLAS	JOURNAL OF CLINICAL ONCOLOGY	28,25	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03	Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL; PALLAS groups and investigators	J Clin Oncol. 2021 Dec 7;JCO2102554. doi: 10.1200/JCO.21.02554. Online ahead of print.
GEICAM/2013-05_BIG5-13 (BRAVO)	Clinical Cancer Research	12,53	Niraprib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study	Turner N, Balmana J, Poncet C, Goulioti T, Peck R, Tryfonidis K, Honkoop A, Zoppoli G, Razis E, Johannsson O, Colleoni M, Tutt A, Audeh W, Ignatiadis M, Mailliez A, Tredan O, Musolino A, Vuylsteke P, Juan-Fita M, Macpherson I, Kaufman B, Manso L, Goldstein L, Ellard S, Lang I, Jen K, Adam V, Litiere S, Erban J, Cameron D, on behalf of the BRAVO Steering Committee and the BRAVO investigators	Clin Cancer Res. 2021 Oct 15;27(20):5482-5491. doi: 10.1158/1078-0432.CCR-21-0310. Epub 2021 Jul 22.

ESTUDIO	REVISTA	FACTOR DE IMPACTO	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2003-11_CIBOMA/2004-01_GEICAM/2012-09 (Nanostring)_HR/HER2_IHC-RNA cut-off (Clinic-Aleix Prat)	NPJ Breast Cancer	5,71	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer	Schettini, F., Chic, N., Brasó-Maristany, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo J.M, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios C.H, Lluch A, Martín M, Locci M, De Placido S, Prat A	NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2.
GEICAM/2015-05 (POSITIVE)	The Breast	4,38	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy	Partridge A.H, Niman S.M, Ruggeri M, Peccatori F.A, Azim H.A, Colleoni M, Saura C, Shimizu C, Sætersdal A.B, Kroep J.R, Mailliez A, Warner E, Borges V.F, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee J.E, Walshe J.M, Ruíz Borrego M, Moore H, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith K.L, Piccart M, Korde L.A, Goldhirsch A, Gelber R.D, Pagani O	Breast. 2021 Oct;59:327-338. doi: 10.1016/j.breast.2021.07.021. Epub 2021 Aug 3.
MDSC Luis de la Cruz	Scientific Reports	4,00	CIRCULATING IMMUNE BIOMARKERS IN PERIPHERAL BLOOD CORRELATE WITH CLINICAL OUTCOMES IN ADVANCED BREAST CANCER	Palazón Carrion N, Jiménez-Cortegana C, Sánchez-León M.L, Henao-Carrasco F, Nogales-Fernández E, Chiesa M, Caballero R, Rojo F, Nieto-García M.A, Sánchez-Margalet V, and de la Cruz-Merino L	Sci Rep. 2021 Jul 13;11(1):14426. doi: 10.1038/s41598-021-93838-w.
GEICAM/2006-11 (LEA)	Breast Cancer Research and Treatment	3,471	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy	Polley MC, Dickler MN, Sinnwell J, Tenner K, de la Haba J, Loibl S, Goetz MP, Bergh J, Roberston J, Couch F, Ellis MJ, Martin M	Breast Cancer Res Treat . 2021 Aug;189(1):15-23. doi: 10.1007/s10549-021-06319-z. Epub 2021 Jul 3.

ESTUDIO	REVISTA	FACTOR DE IMPACTO	TÍTULO PUBLICACIÓN	AUTORES	REFERENCIA
GEICAM/2009-01 (ExteNET)	Clin Breast Cancer	2,703	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial	Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group	Clin Breast Cancer. 2021 Feb;21(1):80-91.e7. doi: 10.1016/j.clbc.2020.09.014. Epub 2020 Oct 6.